Who are Antiarrhythmic drug's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): (A) T-V14, Intravenous Lidocaine, IV lignocaine bolus and infusion, IP Lignocaine bolus and infusion, Brinavess (Vernakalant), Antiarrhythmic Drugs.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antiarrhythmic-drug.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Antiarrhythmic drug — Competitive Intelligence Brief

Antiarrhythmic drug (Antiarrhythmic drug) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic agent. Area: Cardiovascular.

marketed Antiarrhythmic agent Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Antiarrhythmic drug (Antiarrhythmic drug) — Hospital San Carlos, Madrid. Antiarrhythmic drugs suppress abnormal electrical activity in the heart to restore normal heart rhythm.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Antiarrhythmic drug TARGET	Antiarrhythmic drug	Hospital San Carlos, Madrid	marketed	Antiarrhythmic agent
(A) T-V14	(A) T-V14	National Taiwan University Hospital	marketed	Class III antiarrhythmic agent
Intravenous Lidocaine	Intravenous Lidocaine	Khon Kaen University	marketed	Local anesthetic; antiarrhythmic agent	Voltage-gated sodium channels
IV lignocaine bolus and infusion	IV lignocaine bolus and infusion	University of Auckland, New Zealand	marketed	Local anesthetic; Class IB antiarrhythmic agent	Voltage-gated sodium channels
IP Lignocaine bolus and infusion	IP Lignocaine bolus and infusion	University of Auckland, New Zealand	marketed	Local anesthetic / Antiarrhythmic agent	Voltage-gated sodium channels
Brinavess (Vernakalant)	Brinavess (Vernakalant)	Medical University of Vienna	marketed	Atrial-selective antiarrhythmic agent	Atrial potassium channels (Kv1.5, Kv4.3) and sodium channels
Antiarrhythmic Drugs	Antiarrhythmic Drugs	Medtronic Cardiac Ablation Solutions	marketed	Antiarrhythmic agents (Class I, II, III, or IV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic agent class)

Hospital San Carlos, Madrid · 1 drug in this class
Kyoto University, Graduate School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antiarrhythmic drug — Competitive Intelligence Brief. https://druglandscape.com/ci/antiarrhythmic-drug. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab